Britain Covid-19 patient vaccine drug Britain

NHS lung cancer patients first in Europe to access new drug that can halt ‘Death Star’ mutation of tumour

Reading now: 651
msn.com

lung cancer patients will be the first in Europe to receive a “ground-breaking” new medicine which can stop the growth of tumours.

The drug sotorasib, also known by the brand name Lumakras, will be fast-tracked to NHS patients after it was proven in clinical trials that it can stop lung cancer growing for six months or more.

The drug targets the mutation on the KRAS gene, found in a quarter of all tumours, which has become known as the “Death Star” mutation because of its spherical appearance and impenetrable nature.

About 600 lung cancer patients will be given the drug initially in England over the next few weeks after an early access deal was struck with the manufacturer Amgen UK.

Read more on msn.com
The website starsalert.com is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA